12.89

1.53% -0.20

Astria Therapeutics Inc (ATXS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Astria Therapeutics Inc stock is traded at $12.89, with a volume of 383.20K. It is down -1.53% in the last 24 hours and up +2.30% over the past month. Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Previous Close:

$13.09

Open:

$13.14

24h Volume:

383.20K

Relative Volume:

0.19

Market Cap:

$735.82M

Revenue:

Net Income/Loss:

$-72.89M

P/E Ratio:

-5.3264

EPS:

-2.42

Net Cash Flow:

$-68.47M

1W Performance:

-0.46%

1M Performance:

+2.30%

6M Performance:

+124.96%

1Y Performance:

+43.70%

1-Day Range:

$12.85

$13.14

1-Week Range:

$12.85

$13.14

52-Week Range:

$3.555

$13.29

Astria Therapeutics Inc Stock (ATXS) Company Profile

Name

Astria Therapeutics Inc

Sector

Healthcare (1131)

Industry

Biotechnology (631)

Phone

617-349-1971

Address

22 BOSTON WHARF ROAD, BOSTON

Employee

Twitter

Next Earnings Date

2025-03-11

Latest SEC Filings

ATXS's Discussions on Twitter

Compare ATXS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATXS Astria Therapeutics Inc	12.89	747.24M	0	-72.89M	-68.47M	-2.42
VRTX Vertex Pharmaceuticals Inc	452.13	115.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.31	81.12B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	400.17	52.54B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	839.99	51.78B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	177.12	37.12B	447.02M	-1.18B	-906.14M	-6.1812

Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-12-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-17-25	Reiterated	H.C. Wainwright	Buy
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Jan-31-25	Initiated	JMP Securities	Mkt Outperform
Jul-29-24	Initiated	TD Cowen	Buy
Mar-28-23	Initiated	Evercore ISI	Outperform

View All

Astria Therapeutics Inc Stock (ATXS) Latest News

Jan 01, 2026

Patterns Watch: Is Astria Therapeutics Inc stock gaining market shareMarket Performance Summary & Capital Efficiency Focused Strategies - moha.gov.vn

Jan 01, 2026

Dec 29, 2025

Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of “Hold” by Brokerages - Defense World

Dec 29, 2025

Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Dec 29, 2025

Dec 25, 2025

Astria Therapeutics’ STAR-0310 Study: A Promising Step Forward - MSN

Dec 25, 2025

Astria Therapeutics Advances Phase 3 Trial for Hereditary Angioedema Treatment - MSN

Dec 25, 2025

Dec 24, 2025

(ATXS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Dec 24, 2025

Dec 23, 2025

Astria Therapeutics IncComplaints filed against Astria in New York Supreme CourtSEC filing - marketscreener.com

Dec 23, 2025

Astria Faces Shareholder Lawsuits Over Planned BioCryst Merger - TipRanks

Dec 23, 2025

Astria Therapeutics Merger with BioCryst Pharmaceuticals - TradingView — Track All Markets

Dec 23, 2025

Dec 20, 2025

Halper Sadeh LLC Encourages ATXS, GDOT, UBFO Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.

Dec 20, 2025

Dec 19, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-ATXS, MBCN, FMNB, and SEMR - The Malaysian Reserve

Dec 19, 2025

Why Astria Therapeutics Inc. stock could outperform in 2025Weekly Market Outlook & High Win Rate Trade Alerts - Улправда

Dec 19, 2025

Why Astria Therapeutics Inc. stock appeals to dividend seekersJuly 2025 Reactions & Accurate Entry/Exit Alerts - DonanımHaber

Dec 19, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ATXS, MBCN, FMNB, and SEMR - Sahm

Dec 19, 2025

Dec 17, 2025

FDA approves BioCryst's oral pellet version of swelling disorder drug for children - Reuters

Dec 12, 2025

Dec 11, 2025

BioCryst Pharmaceuticals announces board chair transition following retirement notice By Investing.com - Investing.com UK

Dec 11, 2025

BioCryst Pharmaceuticals announces board chair transition following retirement notice - Investing.com

Dec 11, 2025

Dec 10, 2025